Damora Therapeutics, Inc.
DMRA
$20.96
$0.050.24%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 72.91% | 133.79% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 12.51% | 767.74% | |||
| Operating Income | -12.51% | -767.74% | |||
| Income Before Tax | 86.18% | -6,305.75% | |||
| Income Tax Expenses | -4.55% | -- | |||
| Earnings from Continuing Operations | 86.16% | -6,307.15% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 86.16% | -6,307.15% | |||
| EBIT | -12.51% | -767.74% | |||
| EBITDA | -12.51% | -768.93% | |||
| EPS Basic | 99.40% | -5,643.54% | |||
| Normalized Basic EPS | 95.46% | -654.83% | |||
| EPS Diluted | 99.40% | -5,643.54% | |||
| Normalized Diluted EPS | 95.46% | -654.83% | |||
| Average Basic Shares Outstanding | 2,216.89% | 11.56% | |||
| Average Diluted Shares Outstanding | 2,216.89% | 11.56% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||